...
首页> 外文期刊>Clinical drug investigation >Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease Implications of Clinical Trials
【24h】

Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease Implications of Clinical Trials

机译:培哚普利与血管紧张素II受体拮抗剂在高血压和冠状动脉疾病中的临床试验意义

获取原文
获取原文并翻译 | 示例
           

摘要

The renin-angiotensin-aldosterone system (RAAS) is now known to play a key role in the pathogenesis of hypertension and a range of other cardiovascular diseases. Two groups of drugs, the ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) have been developed with the aim of improving clinical outcomes by regulating the RAAS in patients with cardiovascular disease. Initial assumptions were that these two drug types might be interchangeable, but ongoing research has revealed differences between them in terms of pharmacology and outcomes in clinical trials. Although both groups of drugs lower blood pressure, studies of the ACE inhibitor perindopril have revealed preservation of beneficial vascular and endothelial effects mediated by bradykinin and nitric oxide. The selective blockade exerted by ARBs is not associated with these effects. Furthermore, examination of clinical endpoints in major clinical trials has provoked discussion about outcomes comparing ACE inhibitors and ARBs, with recent debate focusing on the incidence of myocardial infarction (MI) in patients receiving these agents. Whether there is an actual difference in protection from MI remains unresolved, although available data confirm the benefit and safety of ACE inhibitors, in particular perindopril, for myocardial protection.
机译:现在已知肾素-血管紧张素-醛固酮系统(RAAS)在高血压和一系列其他心血管疾病的发病机理中起关键作用。已经开发出两组药物,即ACE抑制剂和1型血管紧张素II受体拮抗剂(血管紧张素受体阻滞剂[ARBs]),旨在通过调节心血管疾病患者的RAAS改善临床疗效。最初的假设是这两种药物可能是可互换的,但是正在进行的研究表明它们在药理学和临床试验结果方面存在差异。尽管两组药物均可降低血压,但对ACE抑制剂培哚普利的研究表明,缓激肽和一氧化氮介导的有益血管和内皮作用得以保留。 ARB产生的选择性阻滞与这些作用无关。此外,在主要临床试验中对临床终点的检查激起了关于比较ACE抑制剂和ARB的结局的讨论,最近的争论集中在接受这些药物的患者中心肌梗死(MI)的发生率上。尽管现有数据证实了ACE抑制剂(尤其是培哚普利)对心肌的保护具有益处和安全性,但仍未解决对MI的保护是否存在实际差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号